Randomized, Controlled, Double-blind Multicenter Safety Study to Evaluate the Safety and Immunogenicity of Subcutaneous EPO HEXAL vs. ERYPO® in the Treatment of Anemia Associated With Chronic Renal Insufficiency in Predialysis Patients

NCT00701714 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

337

Enrollment

INDUSTRY

Sponsor class

Stopped investigation of adverse events

Conditions

Anemia
Chronic Renal Insufficiency

Interventions

DRUG: HX575 recombinant human erythropoietin alfa
DRUG: ERYPO

Sponsor

Sandoz